{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T14:23:39Z","timestamp":1781706219877,"version":"3.54.5"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,3,12]],"date-time":"2020-03-12T00:00:00Z","timestamp":1583971200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,3,12]],"date-time":"2020-03-12T00:00:00Z","timestamp":1583971200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Science & Technology Major Project \u201cKey New Drug Creation and Manufacturing Program","award":["No. 2018ZX09711002"],"award-info":[{"award-number":["No. 2018ZX09711002"]}]},{"name":"Natural Scientific Foundation of China","award":["No. 81673463"],"award-info":[{"award-number":["No. 81673463"]}]},{"name":"Natural Scientific Foundation of China","award":["No. 81402503"],"award-info":[{"award-number":["No. 81402503"]}]},{"DOI":"10.13039\/501100009330","name":"Science and Technology Foundation of Guangdong Province","doi-asserted-by":"crossref","award":["No, 2016A030312014"],"award-info":[{"award-number":["No, 2016A030312014"]}],"id":[{"id":"10.13039\/501100009330","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Science and technology program of Guangzhou","award":["No. 201802020002"],"award-info":[{"award-number":["No. 201802020002"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Inhibition of ABC transporters is considered the most effective way to circumvent multidrug resistance (MDR). In the present study, we evaluated the MDR modulatory potential of ERK5-IN-1, a potent extracelluar signal regulated kinase 5 (ERK5) inhibitor.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The cytotoxicity and MDR reversal effect of ERK5-IN-1 were assessed by MTT assay. The KBv200-inoculated nude mice xenograft model was used for the in vivo study. Doxorubicin efflux and accumulation were measured by flow cytometry. The modulation of ABCB1 activity was measured by colorimetric ATPase assay and [<jats:sup>125<\/jats:sup>I]-iodoarylazidoprazosin (IAAP) photolabeling assay. Effect of ERK5-IN-1 on expression of ABCB1 and its downstream markers was measured by PCR and\/or Western blot. Cell surface expression and subcellular localization of ABCB1 were tested by flow cytometry and immunofluorescence.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Our results showed that ERK5-IN-1 significantly increased the sensitivity of vincristine, paclitaxel and doxorubicin in KBv200, MCF7\/adr and HEK293\/ABCB1 cells, respectively. This effect was not found in respective drug sensitive parental cell lines. Moreover, in vivo combination studies showed that ERK5-IN-1 effectively enhanced the antitumor activity of paclitaxel in KBv200 xenografts without causing addition toxicity. Mechanistically, ERK5-IN-1 increased intracellular accumulation of doxorubicin dose dependently by directly inhibiting the efflux function of ABCB1. ERK5-IN-1 stimulated the ABCB1 ATPase activity and inhibited the incorporation of [<jats:sup>125<\/jats:sup>I]-iodoarylazidoprazosin (IAAP) into ABCB1 in a concentration-dependent manner. In addition, ERK5-IN-1 treatment neither altered the expression level of ABCB1 nor blocked the phosphorylation of downstream Akt or Erk1\/2. No significant reversal effect was observed on ABCG2-, ABCC1-, MRP7- and LRP-mediated drug resistance.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Collectively, these results indicated that ERK5-IN-1 efficiently reversed ABCB1-mediated MDR by competitively inhibiting the ABCB1 drug efflux function. The use of ERK5-IN-1 to restore sensitivity to chemotherapy or to prevent resistance could be a potential treatment strategy for cancer patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13046-020-1537-9","type":"journal-article","created":{"date-parts":[[2020,3,12]],"date-time":"2020-03-12T11:03:21Z","timestamp":1584011001000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Reversal of ABCB1-related multidrug resistance by ERK5-IN-1"],"prefix":"10.1186","volume":"39","author":[{"given":"Fang","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ZongHeng","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Kin Wah To","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengjun","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Likun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liwu","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,3,12]]},"reference":[{"key":"1537_CR1","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1002\/path.1706","volume":"205","author":"DB Longley","year":"2005","unstructured":"Longley DB, Johnston PG. Molecular mechanisms of drug resistance. J Pathol. 2005;205:275\u201392.","journal-title":"J Pathol"},{"key":"1537_CR2","doi-asserted-by":"publisher","first-page":"28","DOI":"10.3389\/fphar.2013.00028","volume":"4","author":"H Zahreddine","year":"2013","unstructured":"Zahreddine H, Borden KL. Mechanisms and insights into drug resistance in cancer. Front Pharmacol. 2013;4:28.","journal-title":"Front Pharmacol"},{"key":"1537_CR3","doi-asserted-by":"publisher","first-page":"570","DOI":"10.2174\/138920111795164048","volume":"12","author":"AK Tiwari","year":"2011","unstructured":"Tiwari AK, Sodani K, Dai CL, Ashby CR Jr, Chen ZS. Revisiting the ABCs of multidrug resistance in cancer chemotherapy. Curr Pharm Biotechnol. 2011;12:570\u201394.","journal-title":"Curr Pharm Biotechnol"},{"key":"1537_CR4","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/nrc706","volume":"2","author":"MM Gottesman","year":"2002","unstructured":"Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer. 2002;2:48\u201358.","journal-title":"Nat Rev Cancer"},{"key":"1537_CR5","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1186\/1756-9966-28-144","volume":"28","author":"WQ Hu","year":"2009","unstructured":"Hu WQ, Peng CW, Li Y. The expression and significance of P-glycoprotein, lung resistance protein and multidrug resistance-associated protein in gastric cancer. J Exp Clin Cancer Res. 2009;28:144.","journal-title":"J Exp Clin Cancer Res"},{"key":"1537_CR6","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1186\/s13046-018-0967-0","volume":"37","author":"IC Salaroglio","year":"2018","unstructured":"Salaroglio IC, Gazzano E, Abdullrahman A, Mungo E, Castella B, Abd-Elrahman G, et al. Increasing intratumor C\/EBP-beta LIP and nitric oxide levels overcome resistance to doxorubicin in triple negative breast cancer. J Exp Clin Cancer Res. 2018;37:286.","journal-title":"J Exp Clin Cancer Res"},{"key":"1537_CR7","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1186\/1479-7364-3-3-281","volume":"3","author":"V Vasiliou","year":"2009","unstructured":"Vasiliou V, Vasiliou K, Nebert DW. Human ATP-binding cassette (ABC) transporter family. Hum Genomics. 2009;3:281\u201390.","journal-title":"Hum Genomics"},{"key":"1537_CR8","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1101\/gr.GR-1649R","volume":"11","author":"M Dean","year":"2001","unstructured":"Dean M, Rzhetsky A, Allikmets R. The human ATP-binding cassette (ABC) transporter superfamily. Genome Res. 2001;11:1156\u201366.","journal-title":"Genome Res"},{"key":"1537_CR9","doi-asserted-by":"publisher","first-page":"105","DOI":"10.2217\/14622416.9.1.105","volume":"9","author":"FJ Sharom","year":"2008","unstructured":"Sharom FJ. ABC multidrug transporters: structure, function and role in chemoresistance. Pharmacogenomics. 2008;9:105\u201327.","journal-title":"Pharmacogenomics"},{"key":"1537_CR10","doi-asserted-by":"publisher","first-page":"2897","DOI":"10.1182\/blood.V95.9.2897.009k14_2897_2904","volume":"95","author":"M Pallis","year":"2000","unstructured":"Pallis M, Russell N. P-glycoprotein plays a drug-efflux-independent role in augmenting cell survival in acute myeloblastic leukemia and is associated with modulation of a sphingomyelin-ceramide apoptotic pathway. Blood. 2000;95:2897\u2013904.","journal-title":"Blood"},{"key":"1537_CR11","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.bcp.2013.11.003","volume":"87","author":"F Zhang","year":"2014","unstructured":"Zhang F, Zhang H, Wang Z, Yu M, Tian R, Ji W, et al. P-glycoprotein associates with Anxa2 and promotes invasion in multidrug resistant breast cancer cells. Biochem Pharmacol. 2014;87:292\u2013302.","journal-title":"Biochem Pharmacol"},{"key":"1537_CR12","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.ccr.2004.06.026","volume":"6","author":"G Szakacs","year":"2004","unstructured":"Szakacs G, Annereau JP, Lababidi S, Shankavaram U, Arciello A, Bussey KJ, et al. Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells. Cancer Cell. 2004;6:129\u201337.","journal-title":"Cancer Cell"},{"key":"1537_CR13","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1158\/1078-0432.CCR-0937-3","volume":"10","author":"K Yoh","year":"2004","unstructured":"Yoh K, Ishii G, Yokose T, Minegishi Y, Tsuta K, Goto K, et al. Breast cancer resistance protein impacts clinical outcome in platinum-based chemotherapy for advanced non-small cell lung cancer. Clin Cancer Res. 2004;10:1691\u20137.","journal-title":"Clin Cancer Res"},{"key":"1537_CR14","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1002\/ijc.20589","volume":"114","author":"Y Oda","year":"2005","unstructured":"Oda Y, Saito T, Tateishi N, Ohishi Y, Tamiya S, Yamamoto H, et al. ATP-binding cassette superfamily transporter gene expression in human soft tissue sarcomas. Int J Cancer. 2005;114:854\u201362.","journal-title":"Int J Cancer"},{"key":"1537_CR15","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s13046-015-0275-x","volume":"34","author":"D Westover","year":"2015","unstructured":"Westover D, Li F. New trends for overcoming ABCG2\/BCRP-mediated resistance to cancer therapies. J Exp Clin Cancer Res. 2015;34:159.","journal-title":"J Exp Clin Cancer Res"},{"key":"1537_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drup.2014.11.002","volume":"18","author":"RJ Kathawala","year":"2015","unstructured":"Kathawala RJ, Gupta P, Ashby CR Jr, Chen ZS. The modulation of ABC transporter-mediated multidrug resistance in cancer: a review of the past decade. Drug Resist Updat. 2015;18:1\u201317.","journal-title":"Drug Resist Updat"},{"key":"1537_CR17","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1016\/j.bpj.2012.02.018","volume":"102","author":"X Li-Blatter","year":"2012","unstructured":"Li-Blatter X, Beck A, Seelig A. P-glycoprotein-ATPase modulation: the molecular mechanisms. Biophys J. 2012;102:1383\u201393.","journal-title":"Biophys J"},{"key":"1537_CR18","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/nrd1984","volume":"5","author":"G Szakacs","year":"2006","unstructured":"Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat Rev Drug Discov. 2006;5:219\u201334.","journal-title":"Nat Rev Drug Discov"},{"key":"1537_CR19","doi-asserted-by":"publisher","first-page":"3265","DOI":"10.1158\/1078-0432.CCR-03-0644","volume":"10","author":"A Sandler","year":"2004","unstructured":"Sandler A, Gordon M, De Alwis DP, Pouliquen I, Green L, Marder P, et al. A phase I trial of a potent P-glycoprotein inhibitor, zosuquidar trihydrochloride (LY335979), administered intravenously in combination with doxorubicin in patients with advanced malignancy. Clin Cancer Res. 2004;10:3265\u201372.","journal-title":"Clin Cancer Res"},{"key":"1537_CR20","doi-asserted-by":"publisher","first-page":"4077","DOI":"10.1182\/blood-2010-04-277269","volume":"116","author":"LD Cripe","year":"2010","unstructured":"Cripe LD, Uno H, Paietta EM, Litzow MR, Ketterling RP, Bennett JM, et al. Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the eastern cooperative oncology group 3999. Blood. 2010;116:4077\u201385.","journal-title":"Blood"},{"key":"1537_CR21","doi-asserted-by":"publisher","first-page":"3574","DOI":"10.1158\/1078-0432.CCR-08-0938","volume":"15","author":"J Abraham","year":"2009","unstructured":"Abraham J, Edgerly M, Wilson R, Chen C, Rutt A, Bakke S, et al. A phase I study of the P-glycoprotein antagonist tariquidar in combination with vinorelbine. Clin Cancer Res. 2009;15:3574\u201382.","journal-title":"Clin Cancer Res"},{"key":"1537_CR22","doi-asserted-by":"publisher","first-page":"11012","DOI":"10.1158\/0008-5472.CAN-07-2686","volume":"67","author":"Z Shi","year":"2007","unstructured":"Shi Z, Peng XX, Kim IW, Shukla S, Si QS, Robey RW, et al. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance. Cancer Res. 2007;67:11012\u201320.","journal-title":"Cancer Res"},{"key":"1537_CR23","doi-asserted-by":"publisher","first-page":"7905","DOI":"10.1158\/0008-5472.CAN-08-0499","volume":"68","author":"CL Dai","year":"2008","unstructured":"Dai CL, Tiwari AK, Wu CP, Su XD, Wang SR, Liu DG, et al. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2. Cancer Res. 2008;68:7905\u201314.","journal-title":"Cancer Res"},{"key":"1537_CR24","doi-asserted-by":"publisher","first-page":"887","DOI":"10.2119\/molmed.2011.00444","volume":"18","author":"F Wang","year":"2012","unstructured":"Wang F, Mi YJ, Chen XG, Wu XP, Liu Z, Chen SP, et al. Axitinib targeted cancer stemlike cells to enhance efficacy of chemotherapeutic drugs via inhibiting the drug transport function of ABCG2. Mol Med. 2012;18:887\u201398.","journal-title":"Mol Med"},{"key":"1537_CR25","doi-asserted-by":"publisher","first-page":"7981","DOI":"10.1158\/0008-5472.CAN-10-0111","volume":"70","author":"YJ Mi","year":"2010","unstructured":"Mi YJ, Liang YJ, Huang HB, Zhao HY, Wu CP, Wang F, et al. Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters. Cancer Res. 2010;70:7981\u201391.","journal-title":"Cancer Res"},{"key":"1537_CR26","doi-asserted-by":"publisher","first-page":"4431","DOI":"10.1158\/0008-5472.CAN-13-3553","volume":"74","author":"XK Wang","year":"2014","unstructured":"Wang XK, He JH, Xu JH, Ye S, Wang F, Zhang H, et al. Afatinib enhances the efficacy of conventional chemotherapeutic agents by eradicating cancer stem-like cells. Cancer Res. 2014;74:4431\u201345.","journal-title":"Cancer Res"},{"key":"1537_CR27","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.ejmech.2013.10.052","volume":"70","author":"X Deng","year":"2013","unstructured":"Deng X, Elkins JM, Zhang J, Yang Q, Erazo T, Gomez N, et al. Structural determinants for ERK5 (MAPK7) and leucine rich repeat kinase 2 activities of benzo[e]pyrimido-[5,4-b]diazepine-6(11H)-ones. Eur J Med Chem. 2013;70:758\u201367.","journal-title":"Eur J Med Chem"},{"key":"1537_CR28","doi-asserted-by":"publisher","first-page":"8301","DOI":"10.1038\/sj.onc.1208026","volume":"23","author":"H Song","year":"2004","unstructured":"Song H, Jin X, Lin J. Stat3 upregulates MEK5 expression in human breast cancer cells. Oncog. 2004;23:8301\u20139.","journal-title":"Oncog"},{"key":"1537_CR29","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1038\/sj.onc.1206154","volume":"22","author":"PB Mehta","year":"2003","unstructured":"Mehta PB, Jenkins BL, McCarthy L, Thilak L, Robson CN, Neal DE, et al. MEK5 overexpression is associated with metastatic prostate cancer, and stimulates proliferation, MMP-9 expression and invasion. Oncogene. 2003;22:1381\u20139.","journal-title":"Oncogene."},{"key":"1537_CR30","doi-asserted-by":"publisher","first-page":"2978","DOI":"10.1038\/sj.onc.1210963","volume":"27","author":"SR McCracken","year":"2008","unstructured":"McCracken SR, Ramsay A, Heer R, Mathers ME, Jenkins BL, Edwards J, et al. Aberrant expression of extracellular signal-regulated kinase 5 in human prostate cancer. Oncogene. 2008;27:2978\u201388.","journal-title":"Oncogene."},{"key":"1537_CR31","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.ccr.2010.08.008","volume":"18","author":"Q Yang","year":"2010","unstructured":"Yang Q, Deng X, Lu B, Cameron M, Fearns C, Patricelli MP, et al. Pharmacological inhibition of BMK1 suppresses tumor growth through promyelocytic leukemia protein. Cancer Cell. 2010;18:258\u201367.","journal-title":"Cancer Cell"},{"key":"1537_CR32","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s00280-003-0742-5","volume":"53","author":"L Fu","year":"2004","unstructured":"Fu L, Liang Y, Deng L, Ding Y, Chen L, Ye Y, et al. Characterization of tetrandrine, a potent inhibitor of P-glycoprotein-mediated multidrug resistance. Cancer Chemother Pharmacol. 2004;53:349\u201356.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1537_CR33","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1038\/sj.bjc.6601370","volume":"89","author":"RW Robey","year":"2003","unstructured":"Robey RW, Honjo Y, Morisaki K, Nadjem TA, Runge S, Risbood M, et al. Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity. Br J Cancer. 2003;89:1971\u20138.","journal-title":"Br J Cancer"},{"key":"1537_CR34","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/S0959-8049(01)00356-2","volume":"38","author":"LW Fu","year":"2002","unstructured":"Fu LW, Zhang YM, Liang YJ, Yang XP, Pan QC. The multidrug resistance of tumour cells was reversed by tetrandrine in vitro and in xenografts derived from human breast adenocarcinoma MCF-7\/adr cells. Eur J Cancer. 2002;38:418\u201326.","journal-title":"Eur J Cancer"},{"key":"1537_CR35","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1016\/j.bcp.2007.12.001","volume":"75","author":"RW Robey","year":"2008","unstructured":"Robey RW, Shukla S, Finley EM, Oldham RK, Barnett D, Ambudkar SV, et al. Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1((R)). Biochem Pharmacol. 2008;75:1302\u201312.","journal-title":"Biochem Pharmacol"},{"key":"1537_CR36","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13046-018-0690-x","volume":"37","author":"X Guo","year":"2018","unstructured":"Guo X, To KKW, Chen Z, Wang X, Zhang J, Luo M, et al. Dacomitinib potentiates the efficacy of conventional chemotherapeutic agents via inhibiting the drug efflux function of ABCG2 in vitro and in vivo. J Exp Clin Cancer Res. 2018;37:31.","journal-title":"J Exp Clin Cancer Res"},{"key":"1537_CR37","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1111\/j.1476-5381.2012.01849.x","volume":"166","author":"WJ Zhou","year":"2012","unstructured":"Zhou WJ, Zhang X, Cheng C, Wang F, Wang XK, Liang YJ, et al. Crizotinib (PF-02341066) reverses multidrug resistance in cancer cells by inhibiting the function of P-glycoprotein. Br J Pharmacol. 2012;166:1669\u201383.","journal-title":"Br J Pharmacol"},{"key":"1537_CR38","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/S0076-6879(98)92039-0","volume":"292","author":"SV Ambudkar","year":"1998","unstructured":"Ambudkar SV. Drug-stimulatable ATPase activity in crude membranes of human MDR1-transfected mammalian cells. Methods Enzymol. 1998;292:504\u201314.","journal-title":"Methods Enzymol"},{"key":"1537_CR39","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/j.bcp.2011.12.007","volume":"83","author":"XZ Tong","year":"2012","unstructured":"Tong XZ, Wang F, Liang S, Zhang X, He JH, Chen XG, et al. Apatinib (YN968D1) enhances the efficacy of conventional chemotherapeutical drugs in side population cells and ABCB1-overexpressing leukemia cells. Biochem Pharmacol. 2012;83:586\u201397.","journal-title":"Biochem Pharmacol"},{"key":"1537_CR40","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1634\/theoncologist.8-5-411","volume":"8","author":"GD Leonard","year":"2003","unstructured":"Leonard GD, Fojo T, Bates SE. The role of ABC transporters in clinical practice. Oncologist. 2003;8:411\u201324.","journal-title":"Oncologist"},{"key":"1537_CR41","doi-asserted-by":"publisher","first-page":"621","DOI":"10.2174\/138945011795378540","volume":"12","author":"S Shukla","year":"2011","unstructured":"Shukla S, Ohnuma S, Ambudkar SV. Improving cancer chemotherapy with modulators of ABC drug transporters. Curr Drug Targets. 2011;12:621\u201330.","journal-title":"Curr Drug Targets"},{"key":"1537_CR42","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1186\/s13046-019-1308-7","volume":"38","author":"A Adamska","year":"2019","unstructured":"Adamska A, Domenichini A, Capone E, Damiani V, Akkaya BG, Linton KJ, et al. Pharmacological inhibition of ABCC3 slows tumour progression in animal models of pancreatic cancer. J Exp Clin Cancer Res. 2019;38:312.","journal-title":"J Exp Clin Cancer Res"},{"key":"1537_CR43","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.tips.2014.09.007","volume":"35","author":"M Rask-Andersen","year":"2014","unstructured":"Rask-Andersen M, Zhang J, Fabbro D, Schioth HB. Advances in kinase targeting: current clinical use and clinical trials. Trends Pharmacol Sci. 2014;35:604\u201320.","journal-title":"Trends Pharmacol Sci"},{"key":"1537_CR44","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.tips.2015.04.005","volume":"36","author":"P Wu","year":"2015","unstructured":"Wu P, Nielsen TE, Clausen MH. FDA-approved small-molecule kinase inhibitors. Trends Pharmacol Sci. 2015;36:422\u201339.","journal-title":"Trends Pharmacol Sci"},{"key":"1537_CR45","doi-asserted-by":"publisher","first-page":"6943","DOI":"10.1158\/0008-5472.CAN-05-0641","volume":"65","author":"CH Yang","year":"2005","unstructured":"Yang CH, Huang CJ, Yang CS, Chu YC, Cheng AL, Whang-Peng J, et al. Gefitinib reverses chemotherapy resistance in gefitinib-insensitive multidrug resistant cancer cells expressing ATP-binding cassette family protein. Cancer Res. 2005;65:6943\u20139.","journal-title":"Cancer Res"},{"key":"1537_CR46","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1158\/1535-7163.MCT-15-0939","volume":"15","author":"Z Chen","year":"2016","unstructured":"Chen Z, Chen Y, Xu M, Chen L, Zhang X, To KK, et al. Osimertinib (AZD9291) enhanced the efficacy of chemotherapeutic agents in ABCB1- and ABCG2-overexpressing cells in vitro, in vivo, and ex vivo. Mol Cancer Ther. 2016;15:1845\u201358.","journal-title":"Mol Cancer Ther"},{"key":"1537_CR47","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1038\/sj.bjc.6602569","volume":"92","author":"ML Veronese","year":"2005","unstructured":"Veronese ML, Sun W, Giantonio B, Berlin J, Shults J, Davis L, et al. A phase II trial of gefitinib with 5-fluorouracil, leucovorin, and irinotecan in patients with colorectal cancer. Br J Cancer. 2005;92:1846\u20139.","journal-title":"Br J Cancer"},{"key":"1537_CR48","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1002\/cncr.22535","volume":"109","author":"S Fruehauf","year":"2007","unstructured":"Fruehauf S, Topaly J, Buss EC, Fischer T, Ottmann OG, Emmerich B, et al. Imatinib combined with mitoxantrone\/etoposide and cytarabine is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis. Cancer. 2007;109:1543\u20139.","journal-title":"Cancer"},{"key":"1537_CR49","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1093\/annonc\/mdh188","volume":"15","author":"G Giaccone","year":"2004","unstructured":"Giaccone G, Gonzalez-Larriba JL, van Oosterom AT, Alfonso R, Smit EF, Martens M, et al. Combination therapy with gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, gemcitabine and cisplatin in patients with advanced solid tumors. Ann Oncol. 2004;15:831\u20138.","journal-title":"Ann Oncol"},{"key":"1537_CR50","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1067\/msy.2002.125389","volume":"132","author":"CB Weldon","year":"2002","unstructured":"Weldon CB, Scandurro AB, Rolfe KW, Clayton JL, Elliott S, Butler NN, et al. Identification of mitogen-activated protein kinase kinase as a chemoresistant pathway in MCF-7 cells by using gene expression microarray. Surg. 2002;132:293\u2013301.","journal-title":"Surg"},{"key":"1537_CR51","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.sbi.2007.07.003","volume":"17","author":"K Hollenstein","year":"2007","unstructured":"Hollenstein K, Dawson RJ, Locher KP. Structure and mechanism of ABC transporter proteins. Curr Opin Struct Biol. 2007;17:412\u20138.","journal-title":"Curr Opin Struct Biol"},{"issue":"1","key":"1537_CR52","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1124\/mol.111.076299","volume":"82","author":"XQ Zhao","year":"2012","unstructured":"Zhao XQ, Xie JD, Chen XG, Sim HM, Zhang X, Liang YJ, et al. Neratinib reverses ATP-binding cassette B1-mediated chemotherapeutic drug resistance in vitro, in vivo, and ex vivo. Mol Pharmacol. 2012;82(1):47\u201358.","journal-title":"Mol Pharmacol"},{"key":"1537_CR53","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.ejpb.2012.01.011","volume":"81","author":"HM Aliabadi","year":"2012","unstructured":"Aliabadi HM, Landry B, Mahdipoor P, Hsu CY, Uludag H. Effective down-regulation of breast cancer resistance protein (BCRP) by siRNA delivery using lipid-substituted aliphatic polymers. Eur J Pharm Biopharm. 2012;81:33\u201342.","journal-title":"Eur J Pharm Biopharm"},{"key":"1537_CR54","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.2217\/nnm-2017-0023","volume":"12","author":"MJ Gomes","year":"2017","unstructured":"Gomes MJ, Kennedy PJ, Martins S, Sarmento B. Delivery of siRNA silencing P-gp in peptide-functionalized nanoparticles causes efflux modulation at the blood-brain barrier. Nanomed (Lond). 2017;12:1385\u201399.","journal-title":"Nanomed (Lond)"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-020-1537-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13046-020-1537-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-020-1537-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,12]],"date-time":"2021-03-12T01:13:05Z","timestamp":1615511585000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-020-1537-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,12]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1537"],"URL":"https:\/\/doi.org\/10.1186\/s13046-020-1537-9","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,12]]},"assertion":[{"value":"8 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All the protocols concerning animal experiments were approved by the ethics committee of Sun Yat-sen university Cancer center.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"We have obtained consents to publish this paper from all the participants of this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"50"}}